GLUD1 and familial pancreatic carcinoma: Son and his colleagues had proved that GOT1 mediates the utilization of glutamine in pancreatic cancer; oncogenic KRAS coordinates the shift from canonical type to non-canonical type of glutamine-dependent metabolism by increasing expression of GOT1 and decreasing expression of GLUD1 [9,15,29,30].